Gene · 9757
KMT2B: lysine methyltransferase 2B
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. KMT2B: lysine methyltransferase 2B. Genes, record 9757. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/9757
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9UMN6 | Histone-lysine N-methyltransferase 2B | 2,715 | 4 | Ensembl, GeneID, HGNC |
Source UniProt
Patents38
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| WO 2025238176 A1 | 2025-11-20 | 3 | Q9UMN6 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 12934 | Q9UMN6 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 14496 | Q9UMN6 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 15225 | Q9UMN6 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 14496 | Q9UMN6 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 12934 | Q9UMN6 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 15225 | Q9UMN6 | Espacenet |
| KR 1020250010750 A | 2025-01-21 | 15225 | Q9UMN6 | Espacenet |
| JP 2024109657 A | 2024-08-14 | 15064 | Q9UMN6 | Espacenet |
| US 11807852 B2 | 2023-11-07 | 50 | Q9UMN6 | Espacenet |
1 to 10 of 38
See all 38 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants2,082
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | KMT2B papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 53 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 45 | 2025 |
| ZIADK075003 | Enhancer regulation by H3K4 methyltransferase KMT2D/MLL4 and associated factors | 21 | 2025 |
| R35CA197569 | Mutations of Chromatin and its Modifying Machineries in Malignancies | 17 | 2025 |
| P30CA060553 | The Robert H. Lurie Comprehensive Cancer Center | 12 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 11 | 2025 |
| P01CA066996 | Development of Novel Therapeutic Strategies in Human Leukemias | 10 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 10 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 10 | 2025 |
| ZIADK075017 | Epigenomic regulation of adipogenesis and obesity-associated adipose expansion | 10 | 2025 |
1 to 10 of 2,082Source NIH's project files
See all 2,082 nih grantsPapers2,805
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Nanopore long-read sequencing facilitates accurate diagnosis of KMT2B-related dystonia. | Clin Epigenetics | 2026 | 42754922 | PubTator, text mining | PubMed |
| [Genetic Dystonias]. | Medicina (B Aires) | 2026 | 42659549 | PubTator, text mining | PubMed |
| Chromatin condensates tune nuclear mechanosensing and preserve nuclear integrity to prevent cGAS activation. | EMBO J | 2026 | 42587091 | PubTator, text mining | PubMed |
| BAP1 and UTX are dispensable for transcription-driven Polycomb erasure but essential for enhancer establishment. | J Biol Chem | 2026 | 42567521 | PubTator, text mining | PubMed |
| Rare-Variant Burden Analysis of Dystonia Genes in Parkinson's Disease. | Mov Disord | 2026 | 42541459 | PubTator, text mining | PubMed |
| Correction: Central precocious puberty as the initial manifestation of multisystem involvement caused by de novo heterozygous KMT2B mutation and STS hemizygous deletion: a case report. | Front Endocrinol (Lausanne) | 2026 | 42488006 | PubTator, text mining | PubMed |
| Genetic analysis of childhood-onset dystonia-28 caused by a variant (c.5076G>A) in the KMT2B gene. | Glob Med Genet | 2026 | 42440406 | PubTator, text mining | PubMed |
| Central precocious puberty as the initial manifestation of multisystem involvement caused by de novo heterozygous KMT2B mutation and STS hemizygous deletion: a case report. | Front Endocrinol (Lausanne) | 2026 | 42388856 | PubTator, text mining | PubMed |
| Prohibitins in cancer: Multifaceted regulators of mitochondrial homeostasis, oncogenic signaling, tumor microenvironment, and therapeutic resistance. | Cancer Genet | 2026 | 42341379 | PubTator, text mining | PubMed |
| Diagnostic value of genetic testing in chorea: a retrospective monocentric study. | J Neurol | 2026 | 42321428 | PubTator, text mining | PubMed |
1 to 10 of 2,805
See all 2,805 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/9757
GET https://conductscience.org/api/genes/v1/9757/patents?page=2